Genome wide CRISPR screening reveals a role for sialylation in the tumorigenesis and chemoresistance of acute myeloid leukemia cells

Authors
Lee, Dong-heeKang, Seong-HoChoi, Da-somKo, MinkyungChoi, EunjiAhn, HyejinMin, HophilOh, Soo JinLee, Myeong SupPark, YoonJin, Hyung-seung
Issue Date
2021-07-10
Publisher
ELSEVIER IRELAND LTD
Citation
CANCER LETTERS, v.510, pp.37 - 47
Abstract
Aberrant activation of cytokine and growth factor signal transduction pathways confers enhanced survival and proliferation properties to acute myeloid leukemia (AML) cells. However, the mechanisms underlying the deregulation of signaling pathways in leukemia cells are unclear. To identify genes capable of independently supporting cytokine-independent growth, we employed a genome-wide CRISPR/Cas9-mediated loss-of-function screen in GM-CSF-dependent human AML TF-1 cells. More than 182 genes (p < 0.01) were found to suppress the cytokine-independent growth of TF-1 cells. Among the top hits, genes encoding key factors involved in sialylation biosynthesis were identified; these included CMAS, SLC35A1, NANS, and GNE. Knockout of either CMAS or SLC35A1 enabled cytokine-independent proliferation and survival of AML cells. Furthermore, NSG (NOD/SCID/ IL2R gamma-/-) mice injected with CMAS or SLC35A1-knockout TF-1 cells exhibited a shorter survival than mice injected with wild-type cells. Mechanistically, abrogation of sialylation biosynthesis in TF-1 cells induced a strong activation of ERK signaling, which sensitized cells to MEK inhibitors but conferred resistance to JAK inhibitors. Further, the surface level of alpha 2,3-linked sialic acids was negatively correlated with the sensitivity of AML cell lines to MEK/ERK inhibitors. We also found that sialylation modulated the expression and stability of the CSF2 receptor. Together, these results demonstrate a novel role of sialylation in regulating oncogenic transformation and drug resistance development in leukemia. We propose that altered sialylation could serve as a biomarker for targeted anti-leukemic therapy.
Keywords
N-GLYCOSYLATION; MULTIDRUG-RESISTANCE; SIALIC ACIDS; GROWTH; ACTIVATION; EXPRESSION; MUTATIONS; RUXOLITINIB; GEFITINIB; KNOCKOUT; N-GLYCOSYLATION; MULTIDRUG-RESISTANCE; SIALIC ACIDS; GROWTH; ACTIVATION; EXPRESSION; MUTATIONS; RUXOLITINIB; GEFITINIB; KNOCKOUT; Loss of function screening; Sialylation; AML; CMAS
ISSN
0304-3835
URI
https://pubs.kist.re.kr/handle/201004/116690
DOI
10.1016/j.canlet.2021.04.006
Appears in Collections:
KIST Article > 2021
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE